These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11964269)

  • 21. Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy.
    Weiss L; Reich S; Slavin S
    Cancer Invest; 1992; 10(1):19-26. PubMed ID: 1735011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multilineage engraftment with minimal graft-versus-host disease following in utero transplantation of S-59 psoralen/ultraviolet a light-treated, sensitized T cells and adult T cell-depleted bone marrow in fetal mice.
    Bhattacharyya S; Chawla A; Smith K; Zhou Y; Talib S; Wardwell B; Cowan MJ
    J Immunol; 2002 Dec; 169(11):6133-40. PubMed ID: 12444116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IL-11 separates graft-versus-leukemia effects from graft-versus-host disease after bone marrow transplantation.
    Teshima T; Hill GR; Pan L; Brinson YS; van den Brink MR; Cooke KR; Ferrara JL
    J Clin Invest; 1999 Aug; 104(3):317-25. PubMed ID: 10430613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Effects of immature dendritic cells genetically modified to express sTNFR I on graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL) in allogeneic bone marrow transplantation mice].
    Wang SH; Li DP; Zhang YJ; Zhang P; Zeng LY; Pan XY; Xu KL; Huang YH
    Zhonghua Xue Ye Xue Za Zhi; 2012 Feb; 33(2):88-93. PubMed ID: 22730654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of early post-transplant graft-versus-leukemia effects using intentionally mismatched donor lymphocytes and elimination of alloantigen-primed donor lymphocytes for prevention of graft-versus-host disease.
    Yang I; Weiss L; Abdul-Hai A; Kasir J; Reich S; Slavin S
    Cancer Res; 2005 Nov; 65(21):9735-40. PubMed ID: 16266994
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of graft-versus-host disease in mice using a suicide gene expressed in T lymphocytes.
    Cohen JL; Boyer O; Salomon B; Onclercq R; Charlotte F; Bruel S; Boisserie G; Klatzmann D
    Blood; 1997 Jun; 89(12):4636-45. PubMed ID: 9192790
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of BCL1 leukemia by transplantation of low density fractions of allogeneic bone marrow and spleen cells.
    Palathumpat V; Holm B; Dejbakhsh-Jones S; Strober S
    J Immunol; 1992 May; 148(10):3319-26. PubMed ID: 1578152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Photodepletion with 2-Se-Cl prevents lethal graft-versus-host disease while preserving antitumor immunity.
    Grayson JM; Perez MD; Blevins R; Coe BN; Detty MR; McIver ZA
    PLoS One; 2020; 15(6):e0234778. PubMed ID: 32569289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective elimination of alloreactivity from immunotherapeutic T cells by photodynamic cell purging and memory T-cell sorting.
    Le NT; Chen BJ; Chao NJ
    Cytotherapy; 2005; 7(2):126-33. PubMed ID: 16040391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Large-scale preparation of human anti-third-party veto cytotoxic T lymphocytes depleted of graft-versus-host reactivity: a new source for graft facilitating cells in bone marrow transplantation.
    Aviner S; Yao X; Krauthgamer R; Gan Y; Goren-Arbel R; Klein T; Tabilio A; McMannis JD; Champlin R; Martelli MF; Bachar-Lustig E; Reisner Y
    Hum Immunol; 2005 Jun; 66(6):644-52. PubMed ID: 15993710
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New strategies in allogeneic stem cell transplantation: immunotherapy using irradiated allogeneic T cells.
    Waller EK; Boyer M
    Bone Marrow Transplant; 2000 May; 25 Suppl 2():S20-4. PubMed ID: 10933181
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-12 preserves the graft-versus-leukemia effect of allogeneic CD8 T cells while inhibiting CD4-dependent graft-versus-host disease in mice.
    Yang YG; Sergio JJ; Pearson DA; Szot GL; Shimizu A; Sykes M
    Blood; 1997 Dec; 90(11):4651-60. PubMed ID: 9373279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Depletion of donor-reactive cells as a new concept for improvement of mismatched bone marrow engraftment using reduced-intensity conditioning.
    Prigozhina TB; Elkin G; Khitrin S; Slavin S
    Exp Hematol; 2004 Nov; 32(11):1110-7. PubMed ID: 15539090
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Graft-versus-leukemia effect in minor antigen mismatched chimeras given delayed donor leucocyte infusion: immunoregulatory aspects and role of donor T and ASGM1-positive cells.
    Sefrioui H; Billiau AD; Waer M
    Transplantation; 2000 Jul; 70(2):348-53. PubMed ID: 10933162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The fate of donor T-cell receptor transgenic T cells with known host antigen specificity in a graft-versus-host disease model.
    Dey B; Yang YG; Preffer F; Shimizu A; Swenson K; Dombkowski D; Sykes M
    Transplantation; 1999 Jul; 68(1):141-9. PubMed ID: 10428282
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10).
    Ildstad ST; Wren SM; Bluestone JA; Barbieri SA; Stephany D; Sachs DH
    J Immunol; 1986 Jan; 136(1):28-33. PubMed ID: 2933464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Interleukin-2 inhibits graft-versus-host disease-promoting activity of CD4+ cells while preserving CD4- and CD8-mediated graft-versus-leukemia effects.
    Sykes M; Harty MW; Szot GL; Pearson DA
    Blood; 1994 May; 83(9):2560-9. PubMed ID: 7909457
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alloantigen recognition is critical for CD8 T cell-mediated graft anti-tumor activity against murine BCL1 lymphoma after myeloablative bone marrow transplantation.
    Pillai A; Teo P; George T; Mukhopadhyay A; Dejbakhsh-Jones S; Strober S
    Bone Marrow Transplant; 2007 Sep; 40(5):487-97. PubMed ID: 17603512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Allogeneic versus semiallogeneic F1 bone marrow transplantation into sublethally irradiated MHC-disparate hosts. Effects on mixed lymphoid chimerism, skin graft tolerance, host survival, and alloreactivity.
    Pierce GE
    Transplantation; 1990 Jan; 49(1):138-44. PubMed ID: 2137269
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Repifermin (keratinocyte growth factor-2) reduces the severity of graft-versus-host disease while preserving a graft-versus-leukemia effect.
    Clouthier SG; Cooke KR; Teshima T; Lowler KP; Liu C; Connolly K; Ferrara JL
    Biol Blood Marrow Transplant; 2003 Sep; 9(9):592-603. PubMed ID: 14506661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.